FARN Faron Pharmaceuticals Oy

TIDMFARN

RNS Number : 2403J

Faron Pharmaceuticals Oy

21 December 2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron's financial calendar for 2021

Company announcement, 21 December 2020 at 9.00 am (EET)

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces the following dates for the Company's financial reporting in 2021:

   25 March        Financial statement release for the full year 2020 and 

Annual Report 2020 including financial statements for the full year

   26 August       Half-year financial report for the period 1 January to 30 June 2021 

The annual general meeting is planned to be held on Friday 23 April 2021. A separate stock exchange notice will be issued by Faron's board of directors to convene the meeting.

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner, Mark Rogers

Phone: +44 207 213 0880

Panmure Gordon (UK) Limited, Broker

Rupert Dearden

Phone: +44 207 886 2500

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

Email: faron@consilium-comms.com

Stern Investor Relations

Julie Seidel, Naina Zaman

Phone: +1 (212) 362-1200

Email: faron@sternir.com

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen(R) (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen(R) has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine(R), the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several phase III studies around the world against COVID-19. Traumakine(R) is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORKKFBKFBDDPBD

(END) Dow Jones Newswires

December 21, 2020 02:00 ET (07:00 GMT)

Grafico Azioni Faron Pharmaceuticals Oy (LSE:FARN)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Faron Pharmaceuticals Oy (LSE:FARN)
Storico
Da Apr 2023 a Apr 2024